{"id":"https://openalex.org/W4226460714","doi":"https://doi.org/10.1182/blood-2021-151074","title":"First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab Is Effective in Patients with Hcl","display_name":"First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab Is Effective in Patients with Hcl","publication_year":2021,"publication_date":"2021-11-05","ids":{"openalex":"https://openalex.org/W4226460714","doi":"https://doi.org/10.1182/blood-2021-151074"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2021-151074","doi":"https://doi.org/10.1182/blood-2021-151074","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2021-151074","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5101838284","display_name":"Jae H. Park","orcid":"https://orcid.org/0000-0002-2903-5130","observed_orcids":["https://orcid.org/0000-0002-2903-5130","https://orcid.org/0009-0003-2678-9513"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jae H Park","raw_affiliation_strings":["Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013721199","display_name":"Eric S. Winer","orcid":"https://orcid.org/0000-0002-4515-8245","observed_orcids":["https://orcid.org/0000-0002-4515-8245"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Eric S. Winer","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035304428","display_name":"Scott F. Huntington","orcid":"https://orcid.org/0000-0001-7071-6475","observed_orcids":["https://orcid.org/0000-0001-7071-6475"]},"institutions":[{"id":"https://openalex.org/I32971472","display_name":"Yale University","ror":"https://ror.org/03v76x132","country_code":"US","type":"education","lineage":["https://openalex.org/I32971472"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Scott F. Huntington","raw_affiliation_strings":["Department of Internal Medicine, Section of Hematology, Yale University School of Medicine, New Haven, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Internal Medicine, Section of Hematology, Yale University School of Medicine, New Haven, CT","institution_ids":["https://openalex.org/I32971472"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041868948","display_name":"Gottfried von Keudell","orcid":"https://orcid.org/0000-0001-7254-5374","observed_orcids":["https://orcid.org/0000-0001-7254-5374"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gottfried von Keudell","raw_affiliation_strings":["Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086407321","display_name":"Shreya Vemuri","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shreya Vemuri","raw_affiliation_strings":["Memorial Sloan Kettering Cancer Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Memorial Sloan Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032283750","display_name":"Madhulika Shukla","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Madhulika Shukla","raw_affiliation_strings":["Memorial Sloan Kettering Cancer Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Memorial Sloan Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013335673","display_name":"Julie C Kinoshita","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Julie C Kinoshita","raw_affiliation_strings":["Memorial Sloan Kettering Cancer Center, New York,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Memorial Sloan Kettering Cancer Center, New York,","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067208492","display_name":"Victoria Falco","orcid":"https://orcid.org/0000-0001-9324-2110","observed_orcids":["https://orcid.org/0000-0001-9324-2110"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Victoria Falco","raw_affiliation_strings":["Memorial Sloan Kettering Cancer Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Memorial Sloan Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101760493","display_name":"Steven D. Gore","orcid":"https://orcid.org/0000-0002-3649-8758","observed_orcids":["https://orcid.org/0000-0002-3649-8758"]},"institutions":[{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Steven D. Gore","raw_affiliation_strings":["National Institutes of Health, National Cancer Institute, Rockville, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"National Institutes of Health, National Cancer Institute, Rockville, MD","institution_ids":["https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071023119","display_name":"Richard Maury Stone","orcid":"https://orcid.org/0000-0002-7526-2633","observed_orcids":["https://orcid.org/0000-0002-7526-2633"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Richard M. Stone","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025595346","display_name":"Omar Ibrahim Abdel-Wahab","orcid":"https://orcid.org/0000-0002-3907-6171","observed_orcids":["https://orcid.org/0000-0002-3907-6171"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Omar Abdel-Wahab","raw_affiliation_strings":["Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5001124933","display_name":"Martin S. Tallman","orcid":"https://orcid.org/0000-0002-4367-6102","observed_orcids":["https://orcid.org/0000-0002-4367-6102"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Martin S. Tallman","raw_affiliation_strings":["Memorial Sloan Kettering Cancer Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Memorial Sloan Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"138","issue":"Supplement 1","first_page":"43","last_page":"43"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.000699999975040555,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/hairy-cell-leukemia","display_name":"hairy cell leukemia","score":0.859000027179718},{"id":"https://openalex.org/keywords/vemurafenib","display_name":"vemurafenib","score":1.0},{"id":"https://openalex.org/keywords/obinutuzumab","display_name":"obinutuzumab","score":1.0},{"id":"https://openalex.org/keywords/braf-inhibitors","display_name":"BRAF inhibitors","score":0.7509999871253967},{"id":"https://openalex.org/keywords/anti-cd20-monoclonal-antibody","display_name":"anti-CD20 monoclonal antibody","score":0.8259999752044678},{"id":"https://openalex.org/keywords/chemo-free-therapy","display_name":"chemo-free therapy","score":0.824999988079071},{"id":"https://openalex.org/keywords/complete-response","display_name":"complete response","score":0.5979999899864197},{"id":"https://openalex.org/keywords/measurable-residual-disease","display_name":"minimal residual disease","score":0.8479999899864197},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.6039999723434448},{"id":"https://openalex.org/keywords/treatment-safety","display_name":"treatment safety","score":0.34599998593330383},{"id":"https://openalex.org/keywords/drug-related-adverse-events","display_name":"drug-related adverse events","score":0.531000018119812},{"id":"https://openalex.org/keywords/digital-pcr","display_name":"digital PCR","score":0.5239999890327454},{"id":"https://openalex.org/keywords/multiparameter-flow-cytometry","display_name":"multiparameter flow cytometry","score":0.7590000033378601}],"concepts":[{"id":"https://openalex.org/C2777607594","wikidata":"https://www.wikidata.org/wiki/Q389496","display_name":"Obinutuzumab","level":4,"score":0.9262661933898926},{"id":"https://openalex.org/C2776131300","wikidata":"https://www.wikidata.org/wiki/Q423111","display_name":"Vemurafenib","level":4,"score":0.881690263748169},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.838173508644104},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5606513023376465},{"id":"https://openalex.org/C2780653079","wikidata":"https://www.wikidata.org/wiki/Q412323","display_name":"Rituximab","level":3,"score":0.5052207112312317},{"id":"https://openalex.org/C2777866208","wikidata":"https://www.wikidata.org/wiki/Q415939","display_name":"Chlorambucil","level":4,"score":0.4251159429550171},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.35515111684799194},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.34716808795928955},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.18773111701011658},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.14812445640563965},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.14738228917121887},{"id":"https://openalex.org/C2776755627","wikidata":"https://www.wikidata.org/wiki/Q408524","display_name":"Cyclophosphamide","level":3,"score":0.0724712610244751},{"id":"https://openalex.org/C2994587330","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Metastatic melanoma","level":3,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2021-151074","doi":"https://doi.org/10.1182/blood-2021-151074","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2021-151074","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4386927526","https://openalex.org/W4389233305","https://openalex.org/W2980816621","https://openalex.org/W2949766968","https://openalex.org/W2950364027","https://openalex.org/W4389233650","https://openalex.org/W3112698373","https://openalex.org/W2911656649","https://openalex.org/W3160538443","https://openalex.org/W4413774544"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"We":[2,93],"have":[3,66,686],"previously":[4,121],"reported":[5,75,527],">90%":[6],"overall":[7],"response":[8,36],"rates":[9],"of":[10,43,106,129,148,163,178,184,205,224,238,293,311,322,355,382,396,434,448,455,481,529,562,613,660,666,671,677,701,832,847,868,879,896,911,930,941,952,984,996,1005,1017,1029,1044,1056,1067,1078,1089,1101,1112,1123,1134,1145,1156,1223],"the":[11,44,72,104,203,222,279,284,317,323,368,452,478,551,608,643],"BRAF":[12,244],"inhibitor,":[13],"vemurafenib,":[14],"in":[15,41,69,85,110,146,278,283,305,432,441,491,538,638,642,987,1008],"patients":[16,423],"(pts)":[17],"with":[18,49,112,120,208,550,607,633,640,668],"relapsed":[19,48],"or":[20,136,834,849,870,881,898,913,932,943,954,998,1019,1031,1046,1058,1069,1080,1091,1103,1114,1125,1136,1147,1158],"refractory":[21],"(R/R)":[22],"hairy":[23],"cell":[24,592,680],"leukemia":[25],"(HCL)":[26],"(Tiacci":[27,88],"and":[28,46,64,71,108,176,181,187,213,226,243,274,302,340,349,377,408,438,450,461,473,519,574,589,599,617,625,646,674,1219],"Park":[29],"et":[30,54,89],"al.":[31,55,90],"NEJM":[32,91],"2015).":[33],"However,":[34],"complete":[35,558],"(CR)":[37],"rate":[38,78,632],"was":[39,81,167,200,219,251,314,325,430,439,525,536],"observed":[40,537,688],"35-40%":[42],"pts":[45,111,119,282,313,324,332,357,366,391,404,437,443,463,489,541,569,576,602,639,657],"50%":[47],"vemurafenib":[50,84,107,149,225,449,571,578,667,1218],"monotherapy":[51],"(Park":[52],"JH":[53],"Blood":[56],"2018,":[57],"132;392).":[58],"Anti-CD20":[59],"antibodies":[60],"such":[61],"as":[62,229,361],"rituximab":[63,80],"obinutuzumab":[65,109,227,545,563,626,1220],"demonstrated":[67],"efficacy":[68,105,223],"HCL,":[70],"recent":[73],"data":[74],"improved":[76],"CR":[77,232,277,406,425,436,631],"when":[79],"added":[82],"to":[83,102,220,287,316,371,468,557,582,587,691,698,704],"R/R":[86],"HCL":[87,115,123,641,1224],"2021).":[92],"therefore":[94],"initiated":[95],"a":[96,143,269,291,380,648,663,693,988,1009],"phase":[97],"II":[98],"multi-center":[99],"clinical":[100],"trial":[101],"investigate":[103],"newly":[113],"diagnosed":[114],"(NCT03410875).":[116],"Methods:":[117],"Adult":[118],"untreated":[122],"who":[124],"met":[125],"criteria":[126],"for":[127,160,194,290,654,1221],"initiation":[128,387],"treatment":[130,386,1222],"(i.e.,":[131],"ANC":[132,466],"<1.0k/ul,":[133],"Hgb":[134,339,470],"<10.0g/dL":[135],"PLT":[137,341,474],"<100k/ul)":[138],"were":[139,192,333,342,501,555,594],"enrolled.":[140],"Patients":[141],"received":[142],"28-day":[144],"lead":[145],"cycle":[147],"960":[150],"mg":[151],"bid,":[152],"followed":[153],"by":[154,231,247,257,264,363,426],"concurrent":[155],"obinutuzumab-vemurafenib":[156],"from":[157,253,385],"months":[158,395,483],"2-4,":[159],"total":[161,292,310],"duration":[162],"4":[164,207,255,394],"months.":[165],"Obinutuzumab":[166],"administered":[168],"at":[169,202,379,414,596],"1000mg":[170],"IV":[171],"on":[172,682,828,843,864,875,892,907,926,937,948,992,1013,1025,1040,1052,1063,1074,1085,1097,1108,1119,1130,1141,1152],"days":[173,384],"1,":[174],"8,":[175],"15":[177],"month":[179,185,206,254,415,427,447,597],"2,":[180],"day":[182],"1":[183,409,446,534,709],"3":[186],"4.":[188,416],"Vemurafenib":[189,624],"dose":[190,454,572,579],"reductions":[191,573],"allowed":[193],"drug-related":[195],"adverse":[196,372],"events":[197,373],"(AEs).":[198],"Response":[199],"assessed":[201,230,252,362,431],"end":[204],"bone":[209],"marrow":[210],"(BM)":[211],"biopsy":[212],"CT":[214],"scans.":[215],"The":[216,266,296,319,335,496],"primary":[217],"objective":[218],"determine":[221],"combination":[228,627],"rates.":[233],"Secondary":[234],"objectives":[235],"included":[236],"assessment":[237],"safety,":[239],"MRD":[240,250,429,635],"negativity":[241,636],"rate,":[242],"allele":[245],"burden":[246],"digital":[248],"PCR.":[249,265],"BM":[256],"multiparameter":[258],"flow":[259],"cytometry":[260],"and/or":[261],"IgH":[262],"clonality":[263],"study":[267,297,369,397],"adopted":[268],"Simon's":[270],"minimax":[271],"2-stage":[272],"design":[273],"required":[275],"\u22657":[276],"first":[280,285,453,552],"9":[281],"stage":[286],"continue":[288],"accrual":[289,304],"28":[294,356],"pts.":[295],"began":[298],"enrollment":[299],"March":[300],"2018":[301],"completed":[303,392],"February":[306],"2021.":[307],"Results:":[308],"A":[309],"30":[312],"enrolled":[315],"study.":[318],"median":[320,336,381,479,609],"age":[321],"54":[326],"years":[327],"old":[328],"(range,":[329,344,347,351,388,484,615,620],"28-82).":[330],"27":[331,401,422,435],"male.":[334],"pretreatment":[337],"ANC,":[338],"0.8k/ul":[343],"0.0-2.6),":[345],"12.3g/dL":[346],"7.0-15.0),":[348],"83k/ul":[350],"21-153),":[352],"respectively.":[353,476,622],"Sixteen":[354],"had":[358,465,570,577,658],"baseline":[359],"splenomegaly":[360],"CT.":[364],"Three":[365],"discontinued":[367],"due":[370,581,586],"(verrucous":[374],"hyperplasia,":[375],"pneumonia":[376],"rash)":[378],"50":[383],"29-56).":[389],"Twenty-seven":[390],"all":[393,421,488,513,517,548,559,601],"treatments.":[398],"Of":[399],"those":[400],"patients,":[402],"26":[403,433],"achieved":[405,411,424],"(96%)":[407,637],"pt":[410],"PR":[412],"(4%)":[413],"With":[417,477],"no":[418,526,669,675],"further":[419],"treatment,":[420],"10.":[428],"undetectable":[440],"25":[442,459],"(96%).":[444],"After":[445],"before":[451],"obinutuzumab,":[456],"20":[457],"(74%),":[458],"(93%)":[460],"24":[462],"(89%)":[464],"recovery":[467],">1.0K/ul,":[469],">10":[471],"g/dL":[472],"100k/uL,":[475],"follow-up":[480,695],"16.7":[482],"4.9":[485],"-":[486],"36),":[487],"remain":[490],"continuous":[492],"remission":[493,702],"without":[494,564],"relapse.":[495],"most":[497,584],"common":[498],"vemurafenib-related":[499],"AEs":[500],"rash":[502,588],"(61%;":[503],"Gr1/2-14%,":[504],"Gr3-":[505],"46%),":[506],"arthralgia":[507],"(46%;":[508],"Gr1/2-36%,":[509],"Gr3-11%),":[510],"fatigue":[511],"(29%,":[512],"Gr1),":[514,518],"alopecia":[515],"(25%,":[516],"pruritis":[520],"(21%,":[521],"Gr1-2)":[522],"(Table).":[523],"There":[524],"case":[528,670],"febrile":[530,672],"neutropenia":[531,673],"but":[532,554],"grade":[533,543],"fever":[535],"14%.":[539],"Two":[540],"experienced":[542],"2":[544],"infusion":[546,566],"reaction,":[547],"occurring":[549],"infusion,":[553],"able":[556],"intended":[560],"doses":[561],"subsequent":[565],"reactions.":[567],"Five":[568],"12":[575],"interruptions":[580],"AE,":[583],"commonly":[585],"arthralgia.":[590],"T":[591,679],"subsets":[593],"obtained":[595],"5-8":[598],"12;":[600],"showed":[603],"CD4":[604,611],"counts":[605],">200":[606],"absolute":[610],"count":[612],"540":[614],"214-1231)":[616],"639":[618],"cells/ul":[619],"402-1446),":[621],"Conclusion:":[623],"therapy":[628],"induced":[629],"100%":[630],"high":[634],"frontline":[644],"setting,":[645],"is":[647,696],"promising":[649],"chemotherapy-free":[650],"targeted":[651],"therapeutic":[652],"approach":[653],"HCL.":[655],"Most":[656],"normalization":[659],"cytopenia":[661],"after":[662],"4-week":[664],"lead-in":[665],"evidence":[676],"significant":[678],"immunosuppression":[681],"therapy.":[683],"While":[684],"we":[685],"not":[687],"any":[689],"relapse":[690],"date,":[692],"longer":[694],"needed":[697],"assess":[699],"durability":[700],"compared":[703],"purine":[705],"nucleoside-treated":[706],"cohorts.":[707],"Figure":[708,710],"1.":[711],"Disclosures":[712],"Park:":[713],"Amgen:":[714,890,1161],"Consultancy;":[715,717,719,721,723,726,729,731,733,735,738,740,742,747,749,754,758,761,766,768,772,778,815,817,819,821,825,839,853,857,860,889,917,923,961,964,968,980],"Autolus:":[716],"BMS:":[718,795],"PrecisionBio:":[720],"Affyimmune:":[722],"Kura":[724],"Oncology:":[725,975],"Innate":[727,1049],"Pharma:":[728,737,1050,1095],"Intellia:":[730],"Minerva:":[732],"Servier:":[734,765],"Kite":[736],"Curocel:":[739],"Artiva:":[741],"Novartis:":[743,746,753,918,1061],"Consultancy.":[744,751,958],"Winer:":[745],"Takeda:":[748,957],"Abbvie:":[750,916,1150,1177],"Huntington:":[752],"Bayer:":[755],"Honoraria;":[756,764,785,806,809,1037,1182,1185,1189,1193,1198,1202,1206,1211,1213],"SeaGen:":[757],"Thyme":[759],"Inc:":[760,967],"Pharmacyclics:":[762,807],"Consultancy,":[763,784,787,805,808,811,885,902,919,971,976],"Genentech:":[767],"Flatiron":[769],"Health":[770],"Inc.:":[771,1002],"DTRM":[773],"Biopharm:":[774],"Research":[775,781,788,793,796,799,802,886,903,920,972,977,1162,1166,1169,1172,1175,1178],"Funding;":[776,782,794,797,800,803,887,904,921,973,978,1163,1167,1170,1173,1176,1179],"AbbVie:":[777,792],"TG":[779],"Therapeutics:":[780,838,963],"AstraZeneca:":[783],"Celgene:":[786,852],"Funding.":[789],"von":[790],"Keudell:":[791],"Janssen:":[798,818],"Merck:":[801,804,960],"Incyte:":[810],"Honoraria.":[812,1215],"Stone:":[813],"Macrogenics:":[814],"Jazz:":[816],"Innate:":[820],"Glaxo":[822],"Smith":[823],"Kline:":[824],"Gemoab:":[826],"Membership":[827,842,863,874,891,906,925,936,947,991,1012,1024,1039,1051,1062,1073,1084,1096,1107,1118,1129,1140,1151],"an":[829,844,865,876,893,908,927,938,949,993,1014,1026,1041,1053,1064,1075,1086,1098,1109,1120,1131,1142,1153],"entity's":[830,845,866,877,894,909,928,939,950,994,1015,1027,1042,1054,1065,1076,1087,1099,1110,1121,1132,1143,1154],"Board":[831,846,867,878,895,910,929,940,951,995,1016,1028,1043,1055,1066,1077,1088,1100,1111,1122,1133,1144,1155],"Directors":[833,848,869,880,897,912,931,942,953,997,1018,1030,1045,1057,1068,1079,1090,1102,1113,1124,1135,1146,1157],"advisory":[835,850,871,882,899,914,933,944,955,999,1020,1032,1047,1059,1070,1081,1092,1104,1115,1126,1137,1148,1159],"committees;":[836,851,872,883,900,915,934,945,956,1000,1033,1048,1060,1071,1082,1093,1105,1116,1127,1138,1149,1160],"Foghorn":[837],"Elevate":[840],"Bio:":[841,862],"Bristol":[854],"Meyers":[855],"Squibb:":[856],"Boston":[858],"Pharmaceuticals:":[859,1165],"BerGen":[861],"Astellas:":[873],"Arog:":[884],"Aprea:":[888],"Agios:":[901],"Actinium:":[905],"OncoNova:":[922],"Syndax:":[924],"Syntrix/ACI:":[935],"Syros:":[946,1023],"Abdel-Wahab:":[959],"Prelude":[962],"Foundation":[965],"Medicine":[966],"H3B":[969],"Biomedicine:":[970],"LOXO":[974],"Lilly:":[979],"AIChemy:":[981],"Current":[982,1003],"holder":[983,1004],"stock":[985,1006],"options":[986,1007],"privately-held":[989,1010],"company,":[990,1011],"Envisagenics":[1001],"committees.":[1021],"Tallman:":[1022],"NYU":[1034,1190],"Grand":[1035,1187,1191],"Rounds:":[1036,1188,1192],"Kura:":[1038],"Biosight:":[1072,1171],"Roche:":[1083],"Jazz":[1094],"Oncolyze:":[1106],"KAHR:":[1117],"Orsenix:":[1128,1174],"Daiichi-Sankyo:":[1139],"Rafael":[1164],"Glycomimetics:":[1168],"Mayo":[1180],"Clinic:":[1181],"UC":[1183],"DAVIS:":[1184],"Northwell":[1186],"Danbury":[1194],"Hospital":[1195],"Tumor":[1196],"Board:":[1197],"Acute":[1199],"Leukemia":[1200,1204],"Forum:":[1201],"Miami":[1203],"Symposium:":[1205,1210],"New":[1207],"Orleans":[1208],"Cancer":[1209],"ASH:":[1212],"NCCN:":[1214],"OffLabel":[1216],"Disclosure:":[1217]},"counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2022,"cited_by_count":2}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2022-05-05T00:00:00"}